SemaCagri Tre Blend
The most comprehensive metabolic research stack available — combining semaglutide, cagrilintide, and retatrutide mechanisms in one preparation. This hits GLP-1, GIP, glucagon, AND amylin receptors simultaneously, saturating every known appetite and fat-burning pathway for maximum body composition change.
About SemaCagri Tre Blend
The combination of GLP-1 and amylin receptor agonism represents one of the most promising frontiers in metabolic research. Clinical data from the CagriSema program has demonstrated that the dual approach produces weight reduction exceeding either agent alone, suggesting non-redundant appetite suppression pathways. GLP-1 acts primarily through hypothalamic POMC/CART neurons and pancreatic beta cells, while amylin acts through area postrema-mediated satiety signaling. The blend enables researchers to study these synergistic interactions in a single reconstitution.
Full Research Monograph — 4 PubMed CitationsYou May Also Consider
The weight loss revolution — the same molecule in Ozempic that helps millions lose 15-20% of body weight by silencing food cravings and resetting appetite at the brain level.
- Lose 15-20% of body weight without willpower or starvation
- Completely eliminates food noise and constant cravings
Cagrilintide
5mgThe semaglutide amplifier — a long-acting amylin that pairs with GLP-1 drugs to supercharge weight loss. Part of the CagriSema combination that's the next breakthrough.
- Long-acting amylin analog for appetite suppression
- Pairs with semaglutide for enhanced weight loss (CagriSema)
Retatrutide 12mg
12mgThe most powerful weight loss compound ever studied — triple-receptor agonist that achieved 24% body weight loss in trials, outperforming semaglutide by hitting THREE metabolic pathways.
- Triple-action weight loss — targets GLP-1, GIP, AND glucagon receptors
- 24% body weight loss in trials — MORE than semaglutide